Table 1. Patient characteristics.
| Characteristic | No. (%) |
|---|---|
| Age (yr), median (range) | 53 (26-79) |
| Histology | |
| Squamous cell carcinoma | 34 (69.4) |
| Adenocarcinoma/adenosquamous cell carcinoma | 15 (30.6) |
| Stage at initial diagnosis | |
| I-II | 20 (40.8) |
| III-IV | 29 (59.2) |
| Initial treatment with platinum based chemotherapy | |
| Weekly CDDP (definitive CCRT) | 36 (73.5) |
| 5FU+CDDP (postoperative CCRT) | 10 (20.4) |
| Irinotecan + CDDP (postoperative systemic chemotherapy) | 3 (6.1) |
| Second-line chemotherapy | |
| CDDP based | 23 (46.9) |
| CDDP | 7 (14.3) |
| Irinotecan + CDDP | 9 (18.4) |
| Paclitaxel + CDDP | 5 (10.2) |
| Oral fluoropyrimidine* + CDDP | 2 (4.1) |
| CDDP analogue (carboplatin or nedaplatin) based | 26 (53.1) |
| Paclitaxel + carboplatin | 25 (51.0) |
| Nedaplatin | 1 (2.1) |
| Disease site | |
| Pelvic | 14 (28.6) |
| Distant | 29 (59.2) |
| Both | 6 (12.2) |
| Tumor diameter (mm) | |
| <30 | 31 (63.3) |
| ≥30 | 18 (36.7) |
| Platinum free interval (mo), median (range) | 8.2 (1.4-55.8) |
| 0-5 | 17 (34.7) |
| 6-11 | 18 (36.7) |
| ≥12 | 14 (28.6) |
5FU, 5-fluorouracil; CCRT, concurrent chemoradiotherapy; CDDP, cisplatin.
*S-1.